Worsening of myasthenia gravis after administration of injectable long-acting risperidone for treatment of schizophrenia; first case report and a call for caution

Al-Hashel, Jasem Yousef; Ismail, Ismail Ibrahim; John, John K.; Ibrahim, Mohammed; Ali, Mahmoud

doi:10.1016/j.nmd.2016.02.006

Cited by 7 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A review of the literature of case reports published in English in PubMed, Scopus, and Google scholar showed two previous case reports of myasthenia exacerbation on risperidone, a 29-year-old schizophrenic female patient from Kuwait taking the injectable form [16] and a six-year-old female with attention deficit hyperactivity disorder (ADHD) from turkey taking the oral form [8]. In terms of severity of the exacerbation after risperidone administration, it ranged from ptosis and weakness to severe respiratory depression…”

Section: Discussionmentioning

confidence: 99%

Unmasking of Myasthenia Gravis After Introduction of Oral Risperidone in a Schizophrenic Saudi Male: A Case Report

Abualkhair¹,

Almaghrabi²,

Edrees³

et al. 2021

Cureus

View full text Add to dashboard Cite

Myasthenia gravis is an autoimmune disease that affects the neuromuscular junction. It causes generalized muscle weakness that may include the respiratory muscles, potentially leading to a medical emergency known as a myasthenic crisis. This is a case report of a rare incident of a myasthenia gravis exacerbation after administration of the oral antipsychotic risperidone to a schizophrenic patient. Few similar cases have been reported. Although rare, such incidents are dangerous as physicians could easily confuse myasthenia gravis symptoms with extrapyramidal side effects of antipsychotics. This concern should be addressed not just with risperidone but rather with any other antipsychotics that exhibit anticholinergic side effects.

show abstract

Section: Discussionmentioning

confidence: 99%